Paul J Thornalley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1273311/publications.pdf

Version: 2024-02-01

295 papers	27,702 citations	4146 87 h-index	6471 157 g-index
305 all docs	305 docs citations	305 times ranked	17082 citing authors

#	Article	IF	Citations
1	Hexokinase-2-Linked Glycolytic Overload and Unscheduled Glycolysisâ€"Driver of Insulin Resistance and Development of Vascular Complications of Diabetes. International Journal of Molecular Sciences, 2022, 23, 2165.	4.1	22
2	Emerging Glycation-Based Therapeuticsâ€"Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors. International Journal of Molecular Sciences, 2022, 23, 2453.	4.1	18
3	Identification of Novel Circulating miRNAs in Patients with Acute Ischemic Stroke. International Journal of Molecular Sciences, 2022, 23, 3387.	4.1	11
4	Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nature Metabolism, 2022, 4, 651-662.	11.9	356
5	Dicarbonyl stress, protein glycation and the unfolded protein response. Glycoconjugate Journal, 2021, 38, 331-340.	2.7	32
6	Protein glycation â€“ biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine. Redox Biology, 2021, 42, 101920.	9.0	44
7	Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combinationâ€"Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation. Nutrients, 2021, 13, 2374.	4.1	37
8	Studies of Glyoxalase 1-Linked Multidrug Resistance Reveal Glycolysis-Derived Reactive Metabolite, Methylglyoxal, Is a Common Contributor in Cancer Chemotherapy Targeting the Spliceosome. Frontiers in Oncology, 2021, 11, 748698.	2.8	10
9	Dicarbonyl stress and the glyoxalase system. , 2020, , 759-777.		7
10	High fractional excretion of glycation adducts is associated with subsequent early decline in renal function in type 1 diabetes. Scientific Reports, 2020, 10, 12709.	3.3	10
11	Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicityâ€"Opportunity for Repurposed Chemotherapy of COVID-19 Infection. Frontiers in Pharmacology, 2020, 11, 585408.	3.5	23
12	Glycolytic overload-driven dysfunction of periodontal ligament fibroblasts in high glucose concentration, corrected by glyoxalase 1 inducer. BMJ Open Diabetes Research and Care, 2020, 8, e001458.	2.8	19
13	Potential Markers of Dietary Glycemic Exposures for Sustained Dietary Interventions in Populations without Diabetes. Advances in Nutrition, 2020, 11, 1221-1236.	6.4	10
14	Protein Glycation in Plantsâ€"An Under-Researched Field with Much Still to Discover. International Journal of Molecular Sciences, 2020, 21, 3942.	4.1	23
15	A low glycemic diet protects disease-prone Nrf2-deficient mice against age-related macular degeneration. Free Radical Biology and Medicine, 2020, 150, 75-86.	2.9	23
16	Reading patterns of proteome damage by glycation, oxidation and nitration: quantitation by stable isotopic dilution analysis LC-MS/MS. Essays in Biochemistry, 2020, 64, 169-183.	4.7	19
17	Hexokinase-2 Glycolytic Overload in Diabetes and Ischemiaâ€"Reperfusion Injury. Trends in Endocrinology and Metabolism, 2019, 30, 419-431.	7.1	53
18	Activation of the unfolded protein response in high glucose treated endothelial cells is mediated by methylglyoxal. Scientific Reports, 2019, 9, 7889.	3.3	69

#	Article	IF	Citations
19	Urinary Metabolomic Markers of Protein Glycation, Oxidation, and Nitration in Early-Stage Decline in Metabolic, Vascular, and Renal Health. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-15.	4.0	18
20	Glyoxalase 1 Modulation in Obesity and Diabetes. Antioxidants and Redox Signaling, 2019, 30, 354-374.	5.4	62
21	Advanced glycation endproducts, dityrosine and arginine transporter dysfunction in autism - a source of biomarkers for clinical diagnosis. Molecular Autism, 2018, 9, 3.	4.9	58
22	Advanced glycation end products in the pathogenesis of chronic kidney disease. Kidney International, 2018, 93, 803-813.	5.2	239
23	Studies of advanced glycation end products and oxidation biomarkers for type 2 diabetes. BioFactors, 2018, 44, 281-288.	5.4	27
24	Multiple roles of glyoxalase 1-mediated suppression of methylglyoxal glycation in cancer biologyâ€"Involvement in tumour suppression, tumour growth, multidrug resistance and target for chemotherapy. Seminars in Cancer Biology, 2018, 49, 83-93.	9.6	58
25	Glycation- and/or Polyol Pathway-Inducing Complications. , 2018, , 170-179.		1
26	Sulforaphane Delays Fibroblast Senescence by Curbing Cellular Glucose Uptake, Increased Glycolysis, and Oxidative Damage. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-16.	4.0	27
27	Glycation marker glucosepane increases with the progression of osteoarthritis and correlates with morphological and functional changes of cartilage in vivo. Arthritis Research and Therapy, 2018, 20, 131.	3.5	15
28	Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease. Proteome Science, 2018, 16, 4.	1.7	20
29	Involvement of a gutâ€"retina axis in protection against dietary glycemia-induced age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4472-E4481.	7.1	179
30	192.â€ƒINCREASED PROTEIN GLYCATION, OXIDATION AND NITRATION WITH INCREASING SEVERITY OF RHEUMATOID ARTHRITIS IN A CROSS-SECTIONAL STUDY ASSESSED BY ROBUST STABLE ISOTOPIC DILUTION ANALYSIS QUANTITATION. Rheumatology, 2017, 56, .	1.9	0
31	Intracellular Accumulation of Methylglyoxal by Glyoxalase 1 Knock Down Alters Collagen Homoeostasis in L6 Myoblasts. International Journal of Molecular Sciences, 2017, 18, 480.	4.1	23
32	Relation of the protein glycation, oxidation and nitration to the osteocalcin level in obese subjects. Acta Biochimica Polonica, 2017, 64, 415-422.	0.5	8
33	Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET). Oncotarget, 2017, 8, 76961-76973.	1.8	5
34	Glyoxalase 1-knockdown in human aortic endothelial cells â€" effect on the proteome and endothelial function estimates. Scientific Reports, 2016, 6, 37737.	3.3	39
35	Reappraisal of putative glyoxalase 1-deficient mouse and dicarbonyl stress on embryonic stem cellsin vitro. Biochemical Journal, 2016, 473, 4255-4270.	3.7	26
36	The uremic toxin oxythiamine causes functional thiamine deficiency in end-stage renal disease by inhibiting transketolase activity. Kidney International, 2016, 90, 396-403.	5.2	35

#	Article	IF	Citations
37	Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation. Diabetes, 2016, 65, 2282-2294.	0.6	170
38	Quantitation of plasma thiamine, related metabolites and plasma protein oxidative damage markers in children with autism spectrum disorder and healthy controls. Free Radical Research, 2016, 50, S85-S90.	3.3	30
39	Mass spectrometric determination of early and advanced glycation in biology. Glycoconjugate Journal, 2016, 33, 553-568.	2.7	72
40	Protein oxidation, nitration and glycation biomarkers for early-stage diagnosis of osteoarthritis of the knee and typing and progression of arthritic disease. Arthritis Research and Therapy, 2016, 18, 250.	3.5	54
41	Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments. Clinical Science, 2016, 130, 1677-1696.	4.3	124
42	Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics. Glycoconjugate Journal, 2016, 33, 513-525.	2.7	130
43	Dicarbonyl stress in clinical obesity. Glycoconjugate Journal, 2016, 33, 581-589.	2.7	60
44	Biomarkers of early stage osteoarthritis, rheumatoid arthritis and musculoskeletal health. Scientific Reports, 2015, 5, 9259.	3.3	47
45	Frequency modulated translocational oscillations of Nrf2, a transcription factor functioning like a wireless sensor. Biochemical Society Transactions, 2015, 43, 669-673.	3.4	15
46	Factors influencing the development and effectiveness of biomarkers in rheumatoid arthritis and osteoarthritis. International Journal of Clinical Rheumatology, 2015, 10, 313-316.	0.3	0
47	Increased DNA Dicarbonyl Glycation and Oxidation Markers in Patients with Type 2 Diabetes and Link to Diabetic Nephropathy. Journal of Diabetes Research, 2015, 2015, 1-10.	2.3	37
48	Oxygen restriction as challenge test reveals early high-fat-diet-induced changes in glucose and lipid metabolism. Pflugers Archiv European Journal of Physiology, 2015, 467, 1179-1193.	2.8	8
49	Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. Biochemical and Biophysical Research Communications, 2015, 458, 221-226.	2.1	269
50	New development in a blood-based diagnostic test for early-stage arthritis. Biomarkers in Medicine, 2015, 9, 943-945.	1.4	1
51	Hidden Complexities in the Measurement of Fructosyl-Lysine and Advanced Glycation End Products for Risk Prediction of Vascular Complications of Diabetes. Diabetes, 2015, 64, 9-11.	0.6	17
52	Frequency Modulated Translocational Oscillations of Nrf2 Mediate the Antioxidant Response Element Cytoprotective Transcriptional Response. Antioxidants and Redox Signaling, 2015, 23, 613-629.	5.4	63
53	Arginine-directed glycation and decreased HDL plasma concentration and functionality. Nutrition and Diabetes, 2014, 4, e134-e134.	3.2	57
54	Copy number variation of glyoxalase I. Biochemical Society Transactions, 2014, 42, 500-503.	3.4	18

#	Article	IF	Citations
55	Glyoxalase Centennial conference: introduction, history of research on the glyoxalase system and future prospects. Biochemical Society Transactions, 2014, 42, 413-418.	3.4	31
56	A fluorogenic assay for methylglyoxal. Biochemical Society Transactions, 2014, 42, 548-555.	3.4	21
57	Activity, regulation, copy number and function in the glyoxalase system. Biochemical Society Transactions, 2014, 42, 419-424.	3.4	83
58	Assay of methylglyoxal-derived protein and nucleotide AGEs. Biochemical Society Transactions, 2014, 42, 511-517.	3.4	67
59	Dicarbonyl proteome and genome damage in metabolic and vascular disease. Biochemical Society Transactions, 2014, 42, 425-432.	3.4	112
60	Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice. Physiological Reports, 2014, 2, e12043.	1.7	35
61	The Critical Role of Methylglyoxal and Glyoxalase 1 in Diabetic Nephropathy. Diabetes, 2014, 63, 50-52.	0.6	120
62	Special edition of Amino Acids of selected papers from the eleventh international symposium on the Maillard reaction, September 16â€“20, 2012. Amino Acids, 2014, 46, 259-259.	2.7	2
63	Detection of oxidized and glycated proteins in clinical samples using mass spectrometry â€” A user's perspective. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 818-829.	2.4	117
64	Study of an Unusual Advanced Glycation End-Product (AGE) Derived from Glyoxal Using Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2014, 25, 673-683.	2.8	9
65	Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. Nature Protocols, 2014, 9, 1969-1979.	12.0	198
66	Possible role of methylglyoxal and glyoxalase in arthritis. Biochemical Society Transactions, 2014, 42, 538-542.	3.4	35
67	Measurement of glyoxalase gene expression. Biochemical Society Transactions, 2014, 42, 495-499.	3.4	10
68	Assay of methylglyoxal and glyoxal and control of peroxidase interference. Biochemical Society Transactions, 2014, 42, 504-510.	3.4	24
69	Measurement of glyoxalase activities. Biochemical Society Transactions, 2014, 42, 491-494.	3.4	88
70	Aging-Dependent Reduction in Glyoxalase 1 Delays Wound Healing. Gerontology, 2013, 59, 427-437.	2.8	53
71	Are brain and heart tissue prone to the development of thiamine deficiency?. Alcohol, 2013, 47, 215-221.	1.7	8
72	Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood, 2013, 122, 134-142.	1.4	79

#	Article	IF	Citations
73	Dietary and Synthetic Activators of the Antistress Gene Response in Treatment of Renal Disease. , 2012, 22, 195-202.		12
74	Determination of Types and Binding Sites of Advanced Glycation End Products for Substance P. Analytical Chemistry, 2012, 84, 10568-10575.	6.5	10
75	Disturbance of B-vitamin status in people with type 2 diabetes in Indonesiaâ€"Link to renal status, glycemic control and vascular inflammation. Diabetes Research and Clinical Practice, 2012, 95, 415-424.	2.8	23
76	Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature Medicine, 2012, 18, 926-933.	30.7	414
77	Serum Levels of Advanced Glycation Endproducts and Other Markers of Protein Damage in Early Diabetic Nephropathy in Type 1 Diabetes. PLoS ONE, 2012, 7, e35655.	2.5	46
78	Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochemical Journal, 2012, 443, 213-222.	3.7	251
79	Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. Amino Acids, 2012, 42, 1627-1639.	2.7	22
80	Glycation research in amino acids: a place to call home. Amino Acids, 2012, 42, 1087-1096.	2.7	113
81	Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids, 2012, 42, 1133-1142.	2.7	345
82	Amino Acids Glycation Section. Amino Acids, 2012, 42, 1085-1086.	2.7	2
83	Glucose-Induced Down Regulation of Thiamine Transporters in the Kidney Proximal Tubular Epithelium Produces Thiamine Insufficiency in Diabetes. PLoS ONE, 2012, 7, e53175.	2.5	43
84	Unraveling the Biological Roles of Reactive Oxygen Species. Cell Metabolism, 2011, 13, 361-366.	16.2	661
85	Glyoxalase in tumourigenesis and multidrug resistance. Seminars in Cell and Developmental Biology, 2011, 22, 318-325.	5.0	142
86	Glyoxalase in ageing. Seminars in Cell and Developmental Biology, 2011, 22, 293-301.	5.0	154
87	The glyoxalase systemâ€"From microbial metabolism, through ageing to human disease and multidrug resistance. Seminars in Cell and Developmental Biology, 2011, 22, 261.	5.0	11
88	Glyoxalase in diabetes, obesity and related disorders. Seminars in Cell and Developmental Biology, 2011, 22, 309-317.	5.0	205
89	Protein damage in diabetes and uremiaâ€"identifying hotspots of proteome damage where minimal modification is amplified to marked pathophysiological effect. Free Radical Research, 2011, 45, 89-100.	3.3	32
90	Methylglyoxal modification of LDL: proatherogenicity without oxidation opens new paths to prevent cardiovascular disease. Clinical Lipidology, 2011, 6, 631-634.	0.4	3

#	Article	IF	Citations
91	Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy. Diabetes, Obesity and Metabolism, 2011, 13, 577-583.	4.4	52
92	Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cellular and Molecular Life Sciences, 2011, 68, 721-733.	5.4	73
93	Benfotiamine Protects against Peritoneal and Kidney Damage in Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2011, 22, 914-926.	6.1	42
94	Glycation of LDL by Methylglyoxal Increases Arterial Atherogenicity. Diabetes, 2011, 60, 1973-1980.	0.6	140
95	Thiamine in Diabetic Renal Disease: Dietary Insufficiency, Renal Washout, Antistress Gene Response, Therapeutic Supplements, Risk Predictor, and Link to Genetic Susceptibility. , 2011, , 93-104.		0
96	Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia, 2010, 53, 1506-1516.	6.3	120
97	GLO1â€"A novel amplified gene in human cancer. Genes Chromosomes and Cancer, 2010, 49, 711-725.	2.8	95
98	Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance. Nucleic Acids Research, 2010, 38, 5432-5442.	14.5	98
99	Increased Glycation and Oxidative Damage to Apolipoprotein B100 of LDL Cholesterol in Patients With Type 2 Diabetes and Effect of Metformin. Diabetes, 2010, 59, 1038-1045.	0.6	109
100	Vitamin B6, B9 and B12 in diabetic nephropathyâ€"beware. Nature Reviews Endocrinology, 2010, 6, 477-478.	9.6	19
101	Quantitation of Markers of Protein Damage by Glycation, Oxidation, and Nitration in Peritoneal Dialysis. Peritoneal Dialysis International, 2009, 29, 51-56.	2.3	18
102	C. elegans as Model for the Study of High Glucoseâ€“ Mediated Life Span Reduction. Diabetes, 2009, 58, 2450-2456.	0.6	248
103	Advanced Glycation End Products in Extracellular Matrix Proteins Contribute to the Failure of Sensory Nerve Regeneration in Diabetes. Diabetes, 2009, 58, 2893-2903.	0.6	155
104	Hyperglycemic kidney damage in an animal model of prolonged critical illness. Kidney International, 2009, 76, 512-520.	5.2	66
105	Severe thiamine deficiency complicated by weight loss protects against renal ischaemia-reperfusion injury in rats. CKJ: Clinical Kidney Journal, 2009, 2, 182-183.	2.9	2
106	Glyoxalase II does not support methylglyoxal detoxification but serves as a general trypanothione thioesterase in African trypanosomes. Molecular and Biochemical Parasitology, 2009, 163, 19-27.	1.1	36
107	High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia, 2009, 52, 208-212.	6.3	145
108	Thiamine in diabetic nephropathy: a novel treatment modality? Reply to Alkhalaf A, Kleefstra N, Groenier KH et al. [letter]. Diabetologia, 2009, 52, 1214-1216.	6.3	6

#	Article	IF	Citations
109	Quantitative measurement of specific biomarkers for protein oxidation, nitration and glycation in Arabidopsis leaves. Plant Journal, 2009, 59, 661-671.	5.7	71
110	PROGRESS IN UREMIC TOXIN RESEARCH: The Role of EUTox in Uremic Toxin Research. Seminars in Dialysis, 2009, 22, 323-328.	1.3	27
111	PROGRESS IN UREMIC TOXIN RESEARCH: Highlights and Hotspots of Protein Glycation in Endâ€Stage Renal Disease. Seminars in Dialysis, 2009, 22, 400-404.	1.3	62
112	Tissue-specific glucose toxicity induces mitochondrial damage in a burn injury model of critical illness. Critical Care Medicine, 2009, 37, 1355-1364.	0.9	593
113	Reversal of Hyperglycemiaâ€Induced Angiogenesis Deficit of Human Endothelial Cells by Overexpression of Glyoxalase 1<scp>In Vitro</scp>. Annals of the New York Academy of Sciences, 2008, 1126, 262-264.	3.8	44
114	Preparation of Nucleotide Advanced Glycation Endproducts-Imidazopurinone Adducts Formed by Glycation of Deoxyguanosine with Glyoxal and Methylglyoxal. Annals of the New York Academy of Sciences, 2008, 1126, 280-282.	3.8	7
115	The Dicarbonyl Proteome. Annals of the New York Academy of Sciences, 2008, 1126, 124-127.	3.8	75
116	Glyoxalaseâ€1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell, 2008, 7, 260-269.	6.7	251
117	Assay of 3â€Nitrotyrosine in Tissues and Body Fluids by Liquid Chromatography with Tandem Mass Spectrometric Detection. Methods in Enzymology, 2008, 440, 337-359.	1.0	28
118	PROTEIN AND NUCLEOTIDE DAMAGE BY GLYOXAL AND METHYLGLYOXAL IN PHYSIOLOGICAL SYSTEMS - ROLE IN AGEING AND DISEASE. Drug Metabolism and Drug Interactions, 2008, 23, 125-150.	0.3	375
119	Activation of NF-E2â€"Related Factor-2 Reverses Biochemical Dysfunction of Endothelial Cells Induced by Hyperglycemia Linked to Vascular Disease. Diabetes, 2008, 57, 2809-2817.	0.6	214
120	Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress. Biochemical Society Transactions, 2008, 36, 1045-1050.	3.4	149
121	High Glucose Increases Angiopoietin-2 Transcription in Microvascular Endothelial Cells through Methylglyoxal Modification of mSin3A. Journal of Biological Chemistry, 2007, 282, 31038-31045.	3.4	195
122	Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. Nephrology Dialysis Transplantation, 2007, 22, 3381-3390.	0.7	74
123	Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. Kidney International, 2007, 72, 1113-1121.	5.2	74
124	Effect of storage, processing and cooking on glucosinolate content of Brassica vegetables. Food and Chemical Toxicology, 2007, 45, 216-224.	3.6	259
125	Methylglyoxal Modification of mSin3A Links Glycolysis to Angiopoietin-2 Transcription. Cell, 2007, 128, 625.	28.9	7
126	Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE) â€" an introduction. Molecular Nutrition and Food Research, 2007, 51, 1107-1110.	3.3	57

#	Article	IF	Citations
127	Advanced glycation endproducts: what is their relevance to diabetic complications?. Diabetes, Obesity and Metabolism, 2007, 9, 233-245.	4.4	316
128	High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia, 2007, 50, 2164-2170.	6.3	223
129	Endogenous Î±-Oxoaldehydes and Formation of Protein and Nucleotide Advanced Glycation Endproducts in Tissue Damage. Novartis Foundation Symposium, 2007, 285, 229-246.	1.1	48
130	Advanced Glycation End Products in Renal Failure. , 2006, 16, 178-184.		55
131	Unease on the role of glyoxalase 1 in high-anxiety-related behaviour. Trends in Molecular Medicine, 2006, 12, 195-199.	6.7	42
132	Purification of major glucosinolates fromBrassicaceae seeds and preparation of isothiocyanate and amine metabolites. Journal of the Science of Food and Agriculture, 2006, 86, 1271-1280.	3.5	38
133	Quantitative Screening of Protein Glycation, Oxidation, and Nitration Adducts by LC-MS/MS: Protein Damage in Diabetes, Uremia, Cirrhosis, and Alzheimer's Disease. , 2006, , 681-727.		16
134	Increased Dicarbonyl Metabolism in Endothelial Cells in Hyperglycemia Induces Anoikis and Impairs Angiogenesis by RGD and GFOGER Motif Modification. Diabetes, 2006, 55, 1961-1969.	0.6	234
135	Stimulation of Suicidal Erythrocyte Death by Methylglyoxal. Cellular Physiology and Biochemistry, 2006, 18, 223-232.	1.6	212
136	A Novel Therapeutic Approach in Triosephosphate Isomerase Deficiency.. Blood, 2006, 108, 3735-3735.	1.4	0
137	Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clinical Science, 2005, 109, 83-95.	4.3	139
138	Analysis of glucosinolates, isothiocyanates, and amine degradation products in vegetable extracts and blood plasma by LCâ€“MS/MS. Analytical Biochemistry, 2005, 347, 234-243.	2.4	121
139	Dicarbonyl Intermediates in the Maillard Reaction. Annals of the New York Academy of Sciences, 2005, 1043, 111-117.	3.8	357
140	Peptide Mapping of Human Serum Albumin Modified Minimally by Methylglyoxalin Vitroandin Vivo. Annals of the New York Academy of Sciences, 2005, 1043, 260-266.	3.8	62
141	Increased Protein Glycation in Cirrhosis and Therapeutic Strategies to Prevent It. Annals of the New York Academy of Sciences, 2005, 1043, 718-724.	3.8	25
142	Advanced Glycation End Product Free Adducts Are Cleared by Dialysis. Annals of the New York Academy of Sciences, 2005, 1043, 734-739.	3.8	25
143	Highâ€Dose Thiamine Therapy Counters Dyslipidemia and Advanced Glycation of Plasma Protein in Streptozotocinâ€Induced Diabetic Rats. Annals of the New York Academy of Sciences, 2005, 1043, 777-783.	3.8	48
144	Peptide Mapping of Human Hemoglobin Modified Minimally by Methylglyoxalin Vitro. Annals of the New York Academy of Sciences, 2005, 1043, 905-905.	3.8	18

#	Article	IF	Citations
145	Peptide Mapping of Type IV Collagen Modified Minimally by Methylglyoxalin Vitro. Annals of the New York Academy of Sciences, 2005, 1043, 906-906.	3.8	4
146	Protein Glycation and Oxidation in Cola and Pasteurized Milk. Annals of the New York Academy of Sciences, 2005, 1043, 907-907.	3.8	0
147	Protein Glycation Marker Residues and Free Adducts of Cerebrospinal Fluid in Alzheimer's Disease and a Link to Cognitive Impairment. Annals of the New York Academy of Sciences, 2005, 1043, 914-914.	3.8	0
148	Exogenous Methylglyoxal Induces Diabetes-like Microvascular Changes in Rats. Annals of the New York Academy of Sciences, 2005, 1043, 918-918.	3.8	0
149	Advanced Glycation End Product Excretion Rates by Peritoneal Dialysis in End-Stage Renal Disease. Annals of the New York Academy of Sciences, 2005, 1043, 921-921.	3.8	0
150	Removal of Free Advanced Glycation End Products by Hemodialysis. Annals of the New York Academy of Sciences, 2005, 1043, 922-922.	3.8	2
151	Increased Plasma and Urinary Methylglyoxal-Derived Hydroimidazolone in Type 1 Diabetic Patients. Annals of the New York Academy of Sciences, 2005, 1043, 928-928.	3.8	1
152	Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. Journal of Neurochemistry, 2005, 92, 255-263.	3.9	199
153	Assay of advanced glycation endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Molecular Nutrition and Food Research, 2005, 49, 691-699.	3.3	137
154	Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia, 2005, 48, 1590-1603.	6.3	211
155	Glycation free adduct accumulation in renal disease: the new AGE. Pediatric Nephrology, 2005, 20, 1515-1522.	1.7	49
156	Pro-Inflammatory Cytokine Synthesis by Human Monocytes Induced by Proteins Minimally-Modified by Methylglyoxal. , 2005, , 357-362.		1
157	The Potential Role of Thiamine (Vitamin B1) in Diabetic Complications. Current Diabetes Reviews, 2005, 1, 287-298.	1.3	141
158	Glycated and Oxidized Protein Degradation Products Are Indicators of Fasting and Postprandial Hyperglycemia in Diabetes. Diabetes Care, 2005, 28, 2465-2471.	8.6	117
159	Peptide Mapping Identifies Hotspot Site of Modification in Human Serum Albumin by Methylglyoxal Involved in Ligand Binding and Esterase Activity. Journal of Biological Chemistry, 2005, 280, 5724-5732.	3.4	269
160	Profound Mishandling of Protein Glycation Degradation Products in Uremia and Dialysis. Journal of the American Society of Nephrology: JASN, 2005, 16, 1471-1485.	6.1	128
161	Measurement of protein glycation, glycated peptides, and glycation free adducts. Peritoneal Dialysis International, 2005, 25, 522-33.	2.3	16
162	Transcription Factor Nrf2 Is Essential for Induction of NAD(P)H:Quinone Oxidoreductase 1, Glutathione S-Transferases, and Glutamate Cysteine Ligase by Broccoli Seeds and Isothiocyanates. Journal of Nutrition, 2004, 134, 3499S-3506S.	2.9	181

#	Article	IF	Citations
163	Glycation, receptor-mediated cell activation and vascular complications of diabetes. Diabetes and Vascular Disease Research, 2004, 1, 21-22.	2.0	8
164	NÂ-(Carboxymethyl)lysine and 3-DG-Imidazolone Are Major AGE Structures in Protein Modification by 3-Deoxyglucosone. Journal of Biochemistry, 2004, 136, 351-358.	1.7	47
165	High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia, 2004, 47, 2235-2246.	6.3	85
166	Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. Journal of Hepatology, 2004, 41, 913-919.	3.7	59
167	Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Archives of Biochemistry and Biophysics, 2003, 419, 31-40.	3.0	553
168	Increased formation of methylglyoxal and protein glycation, oxidation and nitrosation in triosephosphate isomerase deficiency. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2003, 1639, 121-132.	3.8	121
169	Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism: Clinical and Experimental, 2003, 52, 163-167.	3.4	160
170	Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochemical Journal, 2003, 375, 581-592.	3.7	580
171	Methylglyoxal-Derived Hydroimidazolone Advanced Glycation End-Products of Human Lens Proteins. , 2003, 44, 5287.		250
172	Prevention of Incipient Diabetic Nephropathy by High-Dose Thiamine and Benfotiamine. Diabetes, 2003, 52, 2110-2120.	0.6	348
173	Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochemical Society Transactions, 2003, 31, 1372-1377.	3.4	118
174	Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis. Biochemical Society Transactions, 2003, 31, 1394-1396.	3.4	30
175	Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochemical Society Transactions, 2003, 31, 1417-1422.	3.4	142
176	Glyoxalase I â€“ structure, function and a critical role in the enzymatic defence against glycation. Biochemical Society Transactions, 2003, 31, 1343-1348.	3.4	547
177	Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochemical Society Transactions, 2003, 31, 1423-1425.	3.4	140
178	Isothiocyanates: mechanism of cancer chemopreventive action. Anti-Cancer Drugs, 2002, 13, 331-338.	1.4	123
179	Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to NâŠ-carboxymethyl-lysine- and NâŠ-(1-carboxyethyl)lysine-modified albumin. Biochemical Journal, 2002, 364, 1-14.	3.7	307
180	Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. Biochemical Journal, 2002, 364, 15-24.	3.7	143

#	Article	IF	Citations
181	Glycation in diabetic neuropathy: Characteristics, consequences, causes, and therapeutic options. International Review of Neurobiology, 2002, 50, 37-57.	2.0	187
182	Estimation of Î±-oxoaldehydes formed from the degradation of glycolytic intermediates and glucose fragmentation in blood plasma of human subjects with uraemia. International Congress Series, 2002, 1245, 181-182.	0.2	14
183	Novel anti-glycation therapeutic agents: glyoxalase I mimetics. International Congress Series, 2002, 1245, 107-111.	0.2	13
184	Kinetics and mechanism of the reaction of metformin with methylglyoxal. International Congress Series, 2002, 1245, 355-356.	0.2	23
185	Reaction kinetics of the scavenging of Î±-oxoaldehydes by aminoguanidine under physiological conditions. International Congress Series, 2002, 1245, 513-515.	0.2	3
186	Assay of early and advanced glycation adducts by enzymatic hydrolysis of proteins and HPLC of 6-aminoquinolylcarbonyl adducts. International Congress Series, 2002, 1245, 279-283.	0.2	1
187	Comparison of in vitro protein modification with advanced glycation endproduct (AGE) precursors methylglyoxal, glyoxal, 3-deoxyglucosone and glucose using mass spectrometry. International Congress Series, 2002, 1245, 353-354.	0.2	2
188	In vitro kinetics of AGE formation with PD fluid resembles that of glucose degradation products rather than glucose. International Congress Series, 2002, 1245, 475-477.	0.2	0
189	Human serum albumin minimally modified by methylglyoxal binds to human mononuclear leukocytes via the RAGE receptor and is displaced by NÎµ-carboxymethyl-lysine and hydroimidazolone AGE epitopes. International Congress Series, 2002, 1245, 77-81.	0.2	8
190	Detection of 3-deoxyglucosone-derived AGE structures in vitro. International Congress Series, 2002, 1245, 239-242.	0.2	2
191	Idiopathic hypoalbuminemia explained by reduced synthesis rate and an increased catabolic rate. Clinical Biochemistry, 2002, 35, 545-553.	1.9	7
192	Signal transduction activated by the cancer chemopreventive isothiocyanates: cleavage of BID protein, tyrosine phosphorylation and activation of JNK. British Journal of Cancer, 2001, 84, 670-673.	6.4	78
193	Involvement of glutathione metabolism in the cytotoxicity of the phenethyl isothiocyanate and its cysteine conjugate to human leukaemia cells in vitro11Abbreviations: BSO, l-buthionine sulphoximine; DNP-SG, S-2,4-dinitrophenylglutathione; DTT, dithiothreitol; GST, glutathione S-transferase; HL60, human leukaemia 60; JNK1, c-Jun N-terminal kinase 1; ML-1, human myeloblastic leukaemia-1; PEITC, phenethyl isothiocyanate; PETC, N-phenethylthiocarbamoyl; PETC-Cys, S-(N-phenethylthiocarbamoyl)cysteine; PETC-SG, S. Biochemical Pharmacology, 2001, 61, 1465-1477.	4.4	120
194	Suppression of the Accumulation of Triosephosphates and Increased Formation of Methylglyoxal in Human Red Blood Cells during Hyperglycaemia by Thiamine In Vitro. Journal of Biochemistry, 2001, 129, 543-549.	1.7	96
195	Antitumour activity of sphingoid base adducts of phenethyl isothiocyanate. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 53-54.	2.2	10
196	Mass spectrometric monitoring of albumin in uremia. Kidney International, 2000, 58, 2228-2234.	5.2	64
197	Kinetics and mechanism of the reaction of aminoguanidine with the Î±-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochemical Pharmacology, 2000, 60, 55-65.	4.4	190
198	Studies on the mechanism of the inhibition of human leukaemia cell growth by dietary isothiocyanates and their cysteine adducts in vitro. Biochemical Pharmacology, 2000, 60, 221-231.	4.4	145

#	Article	IF	Citations
199	Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochemical Journal, 1999, 344, 109-116.	3.7	1,031
200	Discussion. Biochemical Pharmacology, 1999, 57, 583-588.	4.4	8
201	Rapid hydrolysis and slow Î±,Î²-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochemical Pharmacology, 1999, 57, 303-307.	4.4	58
202	Accumulation of Î±-oxoaldehydes during oxidative stress: a role in cytotoxicity. Biochemical Pharmacology, 1999, 58, 641-648.	4.4	225
203	Synthesis of14C-labelled phenethyl isothiocyanate and the cysteine conjugate S-(N-phenethylthiocarbamoyl)cysteine and use under physiological conditions. Journal of Labelled Compounds and Radiopharmaceuticals, 1999, 42, 1069-1074.	1.0	2
204	Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochemical Journal, 1999, 344, 109.	3.7	325
205	Glutathione-dependent detoxification of Î±-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chemico-Biological Interactions, 1998, 111-112, 137-151.	4.0	269
206	Teratogenicity of 3-deoxyglucosone and diabetic embryopathy. Diabetes, 1998, 47, 1960-1966.	0.6	71
207	Effects of Methylglyoxal on Rat Pancreatic Î²-Cells. Biochemical Pharmacology, 1998, 55, 1361-1367.	4.4	50
208	Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis.. Journal of Clinical Investigation, 1998, 101, 1142-1147.	8.2	441
209	Induction of TNFÎ± and IL-1Î² mRNA in monocytes by methylglyoxal- and advanced glycated endproduct-modified human serum albumin. Biochemical Society Transactions, 1997, 25, 250S-250S.	3.4	38
210	Synthesis and secretion of tumour necrosis factor-Î± by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. Immunology Letters, 1997, 58, 139-147.	2.5	51
211	Inhibition of Glyoxalase I (EC4.4.1.5). Expert Opinion on Therapeutic Targets, 1997, 1, 203-206.	1.0	0
212	Antitumor Activity ofS-(p-Bromobenzyl)glutathione Diestersin Vitro:Â A Structureâ^'Activity Study. Journal of Medicinal Chemistry, 1996, 39, 3409-3411.	6.4	43
213	Inhibition of human leukaemia 60 cell growth by mercapturic acid metabolites of phenylethyl isothiocyanate. Food and Chemical Toxicology, 1996, 34, 385-392.	3.6	39
214	Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Biochemical Pharmacology, 1996, 51, 1365-1372.	4.4	151
215	Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-A role in pathogenesis and antiproliferative chemotherapy. General Pharmacology, 1996, 27, 565-573.	0.7	533
216	Inhibition of human leukaemia 60 cell growth by S-d-lactoylglutathione in vitro. Mediation by metabolism to N-d-lactoylcysteine and induction of apoptosis. Leukemia Research, 1996, 20, 17-26.	0.8	18

#	Article	IF	Citations
217	Effect of methylglyoxal on human leukaemia 60 cell growth: Modification of DNA, G1 growth arrest and induction of apoptosis. Leukemia Research, 1996, 20, 397-405.	0.8	175
218	Synthesis and secretion of macrophage colony stimulating factor by mature human monocytes and human monocytic THP-1 cells induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. Immunology Letters, 1996, 53, 7-13.	2.5	39
219	Induction of synthesis and secretion of interleukin 1Î² in the human monocytic THP-1 cells by human serum albumins modified with methylglyoxal and advanced glycation endproducts. Immunology Letters, 1996, 50, 17-21.	2.5	57
220	Reduced glutathione estersâ€"antidotes to toxicity. Cytotoxicity induced by hydrogen peroxide, 1-chloro-2,4-dinitrobenzene, and menadione in murine P388D1 macrophages in vitro. Journal of Biochemical Toxicology, 1995, 10, 245-250.	0.4	7
221	Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. The Protein Journal, 1995, 14, 359-372.	1.1	200
222	Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-d-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Critical Reviews in Oncology/Hematology, 1995, 20, 99-128.	4.4	99
223	Formation of Methylglyoxal-Modified Proteins in vitro and in vivo and Their Involvement in AGE-Related Processes. Contributions To Nephrology, 1995, 112, 24-31.	1.1	31
224	Comparison of the delivery of reduced glutathione into P388D1 cells by reduced glutathione and its mono- and diethyl ester derivatives. Biochemical Pharmacology, 1995, 49, 1475-1482.	4.4	25
225	Facile synthesis of (R)N-2-hydroxyacyl-L-cysteine derivatives: (R)N-2-hydroxyacyl transfer from enzymatically-synthesized (R)S-2-hydroxyacylglutathione derivatives to L-cysteine. Amino Acids, 1995, 9, 185-189.	2.7	1
226	Methylglyoxal, glyoxalases and the development of diabetic complications. Amino Acids, 1994, 6, 15-23.	2.7	66
227	Synthesis of 14C-labelled aminoguanidine. Journal of Labelled Compounds and Radiopharmaceuticals, 1994, 34, 179-184.	1.0	2
228	Prevention of S-d-lactoylglutathione-induced inhibition of human leukaemia 60 cell growth by uridine. Leukemia Research, 1994, 18, 717-722.	0.8	7
229	Methylglyoxal Concentration and Glyoxalase Activities in the Human Lens. Experimental Eye Research, 1994, 59, 497-500.	2.6	86
230	Antimalarial activity in vitro of the glyoxalase I inhibitor diester, S-p-bromobenzylglutathione diethyl ester. Biochemical Pharmacology, 1994, 47, 418-420.	4.4	59
231	The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochemical Pharmacology, 1994, 48, 1865-1870.	4.4	90
232	Glyoxalase System in Clinical Diabetes Mellitus and Correlation with Diabetic Complications. Clinical Science, 1994, 87, 21-29.	4.3	512
233	The Assay of S-D-Lactoylglutathione in Biological Systems. Analytical Biochemistry, 1993, 211, 37-43.	2.4	37
234	A simplified method for the purification of human red blood cell glyoxalase. I. Characteristics, immunoblotting, and inhibitor studies. The Protein Journal, 1993, 12, 111-119.	1.1	45

#	Article	IF	Citations
235	The formation of methylglyoxal from triose phosphates. FEBS Journal, 1993, 212, 101-105.	0.2	477
236	Purification and characterisation of glyoxalase II from human red blood cells. FEBS Journal, 1993, 213, 1261-1267.	0.2	43
237	Characteristics of the inhibition of human promyelocytic leukaemia HL60 cell growth by S-d-lactoylglutathione in vitro. Leukemia Research, 1993, 17, 305-310.	0.8	12
238	Inhibition of proliferation of human leukaemia 60 cells by methylglyoxal in vitro. Leukemia Research, 1993, 17, 397-401.	0.8	36
239	The glyoxalase system in health and disease. Molecular Aspects of Medicine, 1993, 14, 287-371.	6.4	471
240	Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Biochemical Pharmacology, 1993, 46, 805-811.	4.4	134
241	Evidence against the formation of 2-amino-6-(2-formyl-5-hydroxymethyl-pyrrol-l-yl)-hexanoic acid ('pyrraline') as an early-stage product or advanced glycation end product in non-enzymic protein glycation. Clinical Science, 1993, 84, 87-93.	4.3	27
242	Modification of the glyoxalase system in disease processes and prospects for therapeutic strategies. Biochemical Society Transactions, 1993, 21, 531-534.	3.4	50
243	Inhibitors of glyoxalase I: Design, synthesis, inhibitory characteristics and biological evaluation. Biochemical Society Transactions, 1993, 21, 535-540.	3.4	26
244	Modification of the glyoxalase system in clinical diabetes mellitus. Biochemical Society Transactions, 1993, 21, 158S-158S.	3.4	12
245	Inhibition of human leukaemia 60 cell growth by diethyl esterification of the glyoxalase II Inhibitor S-p-nitrobenzoxycarbonylglutathlone in vitro. Biochemical Society Transactions, 1993, 21, 159S-159S.	3.4	2
246	The potentiation of GTP-dependent assenbly of microtubules by S-D-lactoylglutathione. Biochemical Society Transactions, 1993, 21, 160S-160S.	3.4	11
247	The effect of S-D-lactoylglutathione on the movement of neutrophils. Biochemical Society Transactions, 1993, 21, 161S-161S.	3.4	10
248	Formation of methylglyoxal and <scp>d</scp>-lactate in human red blood cells in vitro. Biochemical Society Transactions, 1993, 21, 163S-163S.	3.4	48
249	The assay of S-D-lactoylglutathione in biological systems. Biochemical Society Transactions, 1993, 21, 164S-164S.	3.4	2
250	Inhibition of growth of human leukaemia 60 cells by S-2-hydroxyacylglutathione derivatives. Biochemical Society Transactions, 1993, 21, 165S-165S.	3.4	0
251	Mechanism of the inhibition of growth of human leukaemia 60 cells by S-D-lactoylglutatathione. Biochemical Society Transactions, 1993, 21, 166S-166S.	3.4	2
252	Glyoxalase activity in human tumour cell lines in vitro. Biochemical Society Transactions, 1993, 21, 167S-167S.	3.4	7

#	Article	IF	Citations
253	Inhibition of proliferation of human leukaemia 60 cells by methylglyoxal in vitro. Biochemical Society Transactions, 1993, 21, 168S-168S.	3.4	3
254	The hydrolysis of S-D-lactoylglutathione. Biochemical Society Transactions, 1993, 21, 169S-169S.	3.4	8
255	Binding of methylglyoxal to albumin and formation of fluorescent adducts. Inhibition by arginine, NÎ±-acetylarginine and aminoguanidine. Biochemical Society Transactions, 1993, 21, 170S-170S.	3.4	29
256	Simple chromatographic methods for the purification of human red blood cell glyoxalase I and glyoxalase II to homogeneity. Biochemical Society Transactions, 1993, 21, 171S-171S.	3.4	0
257	Population genetics of human glyoxalases and the development of diabetic complications. Biochemical Society Transactions, 1993, 21, 172S-172S.	3.4	2
258	Modification of the glyoxalase system in streptozotocin-Induced diabetic rats and the effect of the aldose reductase Inhibitor Statil. Biochemical Society Transactions, 1993, 21, 162S-162S.	3.4	6
259	ELECTRON SPIN RESONANCE AND SPIN TRAPPING. , 1993, , 33-69.		1
260	Î³-L-Glutamyl-O-acyl-L-serylglycine derivatives: synthesis, purification and evaluation as inhibitors of glyoxalases. Journal of the Chemical Society Perkin Transactions 1, 1992, , 639-643.	0.9	5
261	Inhibition of growth of human leukaemia 60 cells by S-2-hydroxyacylglutathiones and monoethyl ester derivatives. Biochemical Pharmacology, 1992, 44, 1953-1959.	4.4	15
262	Inhibition of proliferation of human leukaemia 60 cells by diethyl esters of glyoxalase inhibitors in vitro. Biochemical Pharmacology, 1992, 44, 2357-2363.	4.4	71
263	Fluorimetric assay of d-lactate. Analytical Biochemistry, 1992, 206, 12-16.	2.4	89
264	The assay of methylglyoxal in biological systems byderivatization with 1,2-diamino-4,5-dimethoxybenzene. Analytical Biochemistry, 1992, 206, 17-23.	2.4	220
265	Mechanism of the degradation of non-enzymatically glycated proteins under physiological conditions. Studies with the model fructosamine, Nepsilon-(1-deoxy-d-fructos-1-yl)hippuryl-lysine. FEBS Journal, 1992, 210, 729-739.	0.2	108
266	Preparation and characterisation of NÏµ-(1-deoxy-d-fructos-1-yl)hippuryl-lysine. Carbohydrate Research, 1992, 223, 293-298.	2.3	4
267	Synthesis and chromatography of 1,2-diamino-4,5-dimethoxybenzene, 6,7-dimethoxy-2-methylquinoxaline and 6,7-dimethoxy-2,3-dimethylquinoxaline for use in a liquid chromatographic fluorimetric assay of methylglyoxal. Analytica Chimica Acta, 1992, 263, 137-142.	5.4	84
268	S-2-hydroxyacylglutathione-derivatives: enzymatic preparation, purification and characterisation. Journal of the Chemical Society Perkin Transactions 1, 1991, , 3009.	0.9	21
269	Optimisation of non-denaturing polyacrylamide gel electrophoretic analysis of glyoxalase I phenotypes in clinical blood samples. Clinica Chimica Acta, 1991, 204, 137-143.	1.1	8
270	Population genetics of human glyoxalases. Heredity, 1991, 67, 139-142.	2.6	25

#	Article	IF	Citations
271	Synthesis of 14C-labelled methylglyoxal and S-D-lactoylglutathione. Journal of Labelled Compounds and Radiopharmaceuticals, 1990, 28, 1455-1464.	1.0	18
272	The human red blood cell glyoxalase system in diabetes mellitus. Diabetes Research and Clinical Practice, 1989, 7, 115-120.	2.8	113
273	Glyoxalase activity in human red blood cells fractioned by age. Mechanisms of Ageing and Development, 1989, 48, 63-71.	4.6	91
274	Inhibition of proliferation of human promyelocytic leukaemia HL60 cells by S-d-lactoylglutathione in vitro. Leukemia Research, 1988, 12, 897-904.	0.8	61
275	Modification of the glyoxalase system in human HL60 promyelocytic leukemia cells during differentiation to neutrophils in vitro. Biochimica Et Biophysica Acta - General Subjects, 1988, 966, 362-369.	2.4	30
276	S-D-lactoylglutathione in resting and activated human neutrophils. Biochemical and Biophysical Research Communications, 1987, 145, 769-774.	2.1	30
277	Glyoxalase activity during differentiation of human leukaemia cells in vitro. Leukemia Research, 1987, 11, 1141-1148.	0.8	42
278	Reduction of Oxygen by NADH/NADH Dehydrogenase in the Presence of adriamycin. Free Radical Research Communications, 1986, 2, 163-171.	1.8	17
279	Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. BBA - Proteins and Proteomics, 1985, 827, 36-44.	2.1	936
280	The Effect of Nitrone Spin Trapping Agents on Red Cell Glucose Metabolism. Free Radical Research Communications, 1985, 1, 111-117.	1.8	1
281	Free radical production from normal and adriamycin-treated rat cardiac sarcosomes. Biochemical Pharmacology, 1985, 34, 669-674.	4.4	64
282	Red blood cell oxidative metabolism induced by hydroxypyruvaldehyde. Biochemical Pharmacology, 1985, 34, 1157-1164.	4.4	7
283	The haemolytic reactions of 1-acetyl-2-phenylhydrazine and hydrazine: A spin trapping study. Chemico-Biological Interactions, 1984, 50, 339-349.	4.0	27
284	The formation of active oxygen species following activation of 1-naphthol, 1,2- and 1,4-naphthoquinone by rat liver microsomes. Chemico-Biological Interactions, 1984, 48, 195-206.	4.0	38
285	The production of free radicals during the autoxidation of monosaccharides by buffer ions. Carbohydrate Research, 1984, 134, 191-204.	2.3	57
286	The autoxidation of glyceraldehyde and other simple monosaccharides. Experientia, 1984, 40, 244-246.	1.2	102
287	The reaction of superoxide radicals with metal picolinate complexes. Inorganica Chimica Acta, 1983, 78, 139-142.	2.4	30
288	The production of oxygen-centered radicals by Bacillus-Calmette-Guerin-activated macrophages. Biochimica Et Biophysica Acta - Molecular Cell Research, 1983, 763, 245-250.	4.1	32

#	Article	IF	Citations
289	A mechanism for primaquine mediated oxidation of NADPH in red blood cells. Biochemical Pharmacology, 1983, 32, 3571-3575.	4.4	66
290	The production of hydroxyl radicals by adriamycin in red blood cells. FEBS Letters, 1983, 157, 170-172.	2.8	44
291	An EPR study of the production of superoxide radicals by neutrophil NADPH oxidase. FEBS Letters, 1982, 145, 323-326.	2.8	28
292	The generation of hydroxyl radicals following superoxide production by neutrophil NADPH oxidase. FEBS Letters, 1982, 150, 300-302.	2.8	50
293	Free radical production during phenylhydrazine-induced hemolysis. Canadian Journal of Chemistry, 1982, 60, 1528-1531.	1.1	34
294	The inhibition of manganese superoxide dismutase by cacodylate. Inorganica Chimica Acta, 1982, 67, 75-78.	2.4	2
295	Phenyl radical production during the oxidation of phenylhydrazine and in phenylphydrazine-induced haemolysis. FEBS Letters, 1981, 125, 235-238.	2.8	93